moxidectin and Cat-Diseases

Overdoses of macrocyclic lactones in dogs and cats can result in such signs as tremors, ataxia, seizures, coma, and blindness. Dogs with the ABCB1-1Δ gene defect are predisposed to macrocyclic lactone toxicosis at lower dosages than dogs without the defect. Intravenous lipid emulsion therapy has been suggested for treatment of macrocyclic lactone toxicosis but evidence of efficacy is limited. Initial decontamination and supportive care remain the mainstays of therapy for macrocyclic lactone toxicosis.

Topics: Animals; Anthelmintics; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cat Diseases; Cats; Dog Diseases; Dogs; Fat Emulsions, Intravenous; Genotype; Ivermectin; Lactones; Macrolides; Seizures

The macrocyclic lactones (MLs) are parasiticides able to kill a wide variety of arthropods and nematodes. They have a high margin of safety for labeled indications, and ivermectin has become the best-selling antiparasitic in the world. Dogs of certain breeds and mixtures of those breeds have a defect in the ABCB1 gene (formerly MDR1 gene) that results in a lack of functional P-glycoprotein, which leads to accumulation of the MLs in the central nervous system and a higher risk of adverse effects when exposed. There is no specific antidote for ML toxicosis so the most important part of treatment is good supportive care.

Topics: Animals; Anthelmintics; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breeding; Cat Diseases; Cats; Dog Diseases; Dogs; Ivermectin; Lactones; Macrolides; Neurotoxicity Syndromes

Publications discussing the treatment of demodicosis in the dog and cat are reviewed. Based on the evidence in the literature, amitraz rinses at 0.025-0.06% every 7-14 days, and oral daily ivermectin at 300 micro g kg(-1), milbemycin at 2 mg kg(-1) and moxidectin at 400 micro g kg(-1), respectively, can all be recommended for the treatment of generalized canine demodicosis. Ivermectin and moxidectin should be initiated at lower doses and patients monitored for possible adverse effects during therapy. In cats, 2% lime sulfur dips and amitraz rinses at 0.0125-0.025% have been used successfully.

Topics: Administration, Cutaneous; Administration, Oral; Animals; Baths; Cat Diseases; Cats; Dog Diseases; Dogs; Evidence-Based Medicine; Insecticides; Ivermectin; Macrolides; Mite Infestations; Mites; Toluidines

For a number of reasons, several of the more 'traditional' ectoparasiticides in the small animal veterinarian's armoury have been withdrawn over the past few years. New, safer products which are long-acting and easier to apply than the conventional dips, rinses and aerosol sprays of the past have replaced them. However, relatively few such novel acaricidal preparations have become commercially available. Consequently, practitioners and researchers frequently experiment with the drugs they have at their disposal to assess their efficacy against a variety of target acarids when used at different dosages and/or via different routes of administration, compared with those recommended by the manufacturer. This paper reviews the anecdotal and peer-reviewed reports describing the use of modern acaricides in dogs and cats that have recently appeared in the veterinary literature. It should be stressed, however, that no medicine should be prescribed for extra-label use without the informed consent of the owner.

Topics: Administration, Cutaneous; Administration, Oral; Animals; Cat Diseases; Cats; Clinical Trials as Topic; Dog Diseases; Dogs; Insecticides; Ivermectin; Macrolides; Mite Infestations; Mites; Pyrazoles; Scabies; Toluidines

The use of anthelmintics introduced over the past 25 years is discussed. The spectrum of action, efficacy, and toxicity of benzimidazoles, ivermectin, milbemycin, praziquantel, and epsiprantel are considered.

Topics: Animals; Anthelmintics; Anti-Bacterial Agents; Anticestodal Agents; Benzimidazoles; Cat Diseases; Cats; Dog Diseases; Dogs; Fenbendazole; Forecasting; Gastrointestinal Diseases; Ivermectin; Lactones; Macrolides; Mebendazole; Parasitic Diseases; Parasitic Diseases, Animal; Praziquantel

Parasitic bronchopneumonia in domestic cats in Europe, which can manifest with moderate to severe clinical signs, is frequently caused by Troglostrongylus brevior. Data on epizootiological and clinical relevance of cat troglostrongylosis have been published in the last decade but treatment options are still limited. Promising effectiveness data have been generated from clinical cases and field trials for a spot-on formulation containing 1% w/v moxidectin and 10% w/v imidacloprid (Advocate. Sixteen and 20 cats experimentally infected with T. brevior were included in two separate studies, i.e., Study 1 and 2, respectively. Cats were infected with T. brevior third-stage larvae via gastric tube. In both studies cats were randomized to untreated (control, Group 1) and treatment (Group 2) groups. In Study 1 and Study 2, the two groups comprised eight and 10 cats each. Treated cats received Advocate. The experimental model was successful in both studies, as all cats started shedding T. brevior L1 within 25 days post-infection. At necropsy, T. brevior adults were found in 4/8 and 4/10 cats of the control groups in Study 1 and 2, respectively, while none of the treated cats harbored adult worms. The necropsy worm counts in controls did not meet relevant guideline requirements for adequacy of infection, with fewer than six infected cats in the control groups, thus limiting conclusions on treatment efficacy. The fact that 6/8 and 8/10 control cats in Study 1 and 2, respectively, shed L1 up to necropsy while larval shedding ceased in all treated animals after the first treatment provides supporting evidence on the level of efficacy. No remarkable adverse events were recorded in the two studies.. These results indicate that Advocate

Topics: Animals; Cat Diseases; Cats; Macrolides; Metastrongyloidea; Neonicotinoids; Nitro Compounds; Strongylida Infections

To evaluate the efficacy of the 3 major classes of anthelmintics used for the treatment of hookworms in dogs in the US and an extralabel treatment with an FDA-approved product for use in cats in a Labrador kennel with a history of persistent hookworm infections.. 22 dogs housed in a single kennel comprised of the following breeds: 19 Labrador Retrievers, 1 English Cocker Spaniel, 1 Chesapeake Bay Retriever, and 1 Boykin Spaniel.. We performed a fecal egg count (FEC) reduction test using 22 dogs that were allocated randomly to 1 of 5 treatment groups: pyrantel pamoate (Pyrantel pamoate suspension), fenbendazole (Safe-Guard suspension 10%), milbemycin oxime (Interceptor), moxidectin plus imidacloprid (Advantage Multi), and emodepside plus praziquantel (Profender topical solution for cats). FEC was performed on samples collected on days 0 and 11.. FEC reductions for the milbemycin oxime, moxidectin plus imidacloprid, and emodepside plus praziquantel groups were 43.9%, 57.4%, and 100%, respectively. The FEC increased following treatment for the pyrantel and fenbendazole groups.. These data demonstrate that the Ancylostoma caninum infecting the dogs in this kennel are highly resistant to all major anthelmintic classes approved for use in dogs in the US but are susceptible to emodepside. This was the first report of multiple anthelmintic drug-resistant A caninum in a dog kennel that does not involve Greyhounds.

Topics: Ancylostoma; Ancylostomatoidea; Animals; Anthelmintics; Cat Diseases; Dog Diseases; Dogs; Drug Resistance; Feces; Fenbendazole; Georgia; Macrolides; Parasite Egg Count; Praziquantel; Pyrantel Pamoate

The feline lungworm Aelurostrongylus abstrusus affects the lower respiratory tract in cats worldwide. As infections may lead to chronic respiratory changes or even death, preventive treatment in cats with outdoor access is warranted.. The preventive efficacy of a spot-on solution (Bravecto® Plus spot-on solution for cats, MSD) against cat aelurostrongylosis was evaluated using three different preventive treatment regimes in a negative controlled, randomized and partially blinded laboratory efficacy study with 31 purposed-bred cats. The minimum recommended dose of 2.0 mg moxidectin + 40 mg fluralaner/kg bodyweight was applied once 12 (Group [G]1), 8 (G2) or 4 (G3) weeks before experimental infection with 300 third-stage larvae (L3) of A. abstrusus. Another group served as untreated control (G4). Individual faecal samples were analysed as of day 30 post infection (pi) to monitor larvae excretion. Necropsy was performed at days 47-50 pi. The lungs were examined macroscopically for pathological findings and (pre-)adult worms were counted to assess preventive efficacy.. Beginning at day 32-40 pi, all cats of the control group were constantly shedding larvae of A. abstrusus, whereas only one animal of G1 excreted larvae at several consecutive days. In addition, two cats of G1 and G3 and three of G2 were positive on a single occasion. The geometric mean (GM) of the maximum number of excreted larvae was 7574.29 in the control group compared to 1.10 (G1), 1.19 (G2) and 0.53 (G3), resulting in a GM reduction of > 99.9% in all treatment groups. All lungs of the control animals showed severe or very severe alterations at necropsy, while in 94.44% of the treated cats lung pathology was rated as absent or mild. The GM number of (pre-)adult A. abstrusus retrieved from the lungs was 26.57 in the control group, 0.09 in G1 and 0.00 in G2 and G3. Thus, GM worm count reduction was 99.66% in G1 and 100% in G2 and G3.. A single application of Bravecto® Plus spot-on solution at a dose of 2.0 mg moxidectin + 40 mg fluralaner/kg bodyweight reliably prevents cat aelurostrongylosis for at least 12 weeks.

Topics: Animals; Anthelmintics; Cat Diseases; Cats; Female; Isoxazoles; Larva; Lung; Macrolides; Male; Metastrongyloidea; Strongylida Infections; Treatment Outcome

In three randomized, controlled laboratory efficacy studies, the efficacy in the prevention of patent infections of a topical combination of imidacloprid 10%/moxidectin 1% (Advocate® spot-on formulation for cats, Bayer Animal Health GmbH) against larval stages and immature adults of Aelurostrongylus abstrusus, as well as the treatment efficacy of a single or three monthly treatments against adult A. abstrusus, were evaluated.. Cats were experimentally inoculated with 300-800 third-stage larvae (L3). Each group comprised 8 animals and the treatment dose was 10 mg/kg bodyweight (bw) imidacloprid and 1 mg/kg bw moxidectin in each study. Prevention of the establishment of patent infections was evaluated by two treatments at a monthly interval at three different time points before and after challenge infection. Curative efficacy was tested by one or three treatments after the onset of patency. Worm counts at necropsy were used for efficacy calculations.. In Study 1, the control group had a geometric mean (GM) of 28.8 adult nematodes and the single treatment group had a GM of 3.4 (efficacy 88.3%). In Study 2, the control group had a GM of 14.3, the prevention group had a GM of 0 (efficacy 100%), while the treatment group had a GM of 0.1 (efficacy 99.4%). In Study 3, the GM worm burden in the control group was 32.6 compared to 0 in all three prevention groups (efficacy 100% for all of those groups).. The monthly administration of Advocate® reliably eliminated early larval stages and thereby prevented lung damage from and patent infections with A. abstrusus in cats. Regarding treatment, a single application of Advocate® reduced the worm burden, but it did not sufficiently clear the infection. In contrast, three monthly treatments were safe and highly efficacious against A. abstrusus.

Topics: Administration, Topical; Animals; Cat Diseases; Cats; Drug Administration Schedule; Drug Compounding; Female; Larva; Life Cycle Stages; Lung; Macrolides; Male; Metastrongyloidea; Neonicotinoids; Nitro Compounds; Strongylida Infections; Treatment Outcome

Troglostrongylus brevior is a lungworm of wild felids that recently has been recognized as agent of severe respiratory disease in domestic cats in Mediterranean and Balkan countries. Nevertheless, the information on treatment options for feline troglostrongylosis is still poor. The aim of this pilot field trial was to evaluate the efficacy of the spot-on formulation containing 1% w/v moxidectin and 10% w/v imidacloprid (Advocate. The trial was a negative control, multicentre, clinical efficacy study conducted according to the standards of Good Scientific Practice (GSP). Sixteen cats in two study sites, naturally infected with T. brevior, were allocated to an untreated control group (G1, n = 8) or a treatment group (G2, n = 8), according to a randomization list. Animals assigned to G2 were treated with Advocate. All G2 cats were negative for T. brevior L1 at the first post-treatment evaluation (100% efficacy) while G1 cats were persistently shedding L1. The difference of the mean number of L1 per gram between G2 and G1 was statistically significant (P < 0.001). All G1 cats were negative (100% efficacy) for T. brevior L1 at the first post-rescue-treatment evaluation. Therefore, treatment efficacy at study completion was 100% in both groups in terms of stopping the L1 shedding in the faeces of the animals. No adverse effects were observed during the study.. These results indicate that Advocate

Topics: Animals; Cat Diseases; Cats; Drug Combinations; Feces; Female; Greece; Larva; Macrolides; Male; Metastrongyloidea; Neonicotinoids; Nitro Compounds; Respiratory Tract Infections; Strongylida Infections

A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/ml) (Bravecto® Plus) was developed for the treatment of nematode infections as well as providing 12 weeks of protection against insect and acarine parasites in cats. The effectiveness and safety of this product against feline gastrointestinal nematodes was assessed in naturally-infested, client-owned cats under field conditions in Albania, Bulgaria, Germany and Hungary.. To be eligible for enrollment in this investigator-blinded study cats had to be at least 10 weeks-old, weigh at least 1.2 kg, be clinically healthy, and have a faecal sample testing positive for nematodes no more than eight days prior to treatment. Cats were stratified into blocks of three in order of presentation at each center and randomly allocated in a 2:1 ratio to be treated topically on Day 0 with fluralaner plus moxidectin (minimum dose rates 40 mg/kg and 2 mg/kg, respectively) or emodepside plus praziquantel (minimum dose rates 3 mg/kg and 12 mg/kg, respectively) (Profender®). Faecal samples were collected from cats prior to treatment and 14 ± 4 days later.. There were 182 cats randomized to the fluralaner plus moxidectin group, and 91 to the emodepside plus praziquantel group. Prior to treatment the most commonly identified nematode egg was Toxocara cati, found in 79.1 and 82.4% of cats in the fluralaner plus moxidectin and emodepside plus praziquantel groups, respectively. Eggs of Toxascaris leonina were found in 8.2 and 6.6% of cats; of hookworms in 30.8 and 24.2%; and of Capillaria spp. in 7.1 and 4.3%, respectively. After treatment, faecal samples from 98.3% of fluralaner plus moxidectin treated and 96.6% of emodepside plus praziquantel-treated cats were free of nematode ova. Geometric mean faecal egg count reductions for T. cati, the only eggs found in post-treatment faecal samples, were 99.97% and 99.93%, respectively. Treatment with fluralaner plus moxidectin was non-inferior to emodepside plus praziquantel. Both products were safe and well tolerated by cats treated under field conditions.. This field study confirms that, in addition to 12-week extended duration flea and tick control, fluralaner plus moxidectin provides broad spectrum treatment of nematodes in cats.

Topics: Administration, Topical; Animals; Cat Diseases; Cats; Depsipeptides; Europe, Eastern; Feces; Female; Germany; Insecticides; Isoxazoles; Macrolides; Nematoda; Nematode Infections; Parasite Egg Count; Praziquantel; Random Allocation; Single-Blind Method; Siphonaptera; Treatment Outcome

A spot-on formulation containing fluralaner (280 mg/ml) plus moxidectin (14 mg/ml) (Bravecto® Plus) has been developed to provide broad spectrum parasite protection for cats. The effectiveness and safety of this product against ticks and fleas was assessed in a randomized, controlled, 12-week study in client-owned cats in Germany and Spain.. Eligible households containing at least one cat with at least two fleas and/or two ticks were allocated randomly in a 2:1 ratio to a single treatment with fluralaner plus moxidectin on Day 0, or three 4-weekly treatments with fipronil (Frontline®). Veterinary staff, masked to treatment, completed tick and flea counts on each cat at 14 ± 2 (2 weeks), 28 ± 2 (4 weeks), 56 ± 2 (8 weeks) and 84 ± 2 days (12 weeks) after the initial treatment.. In total, 707 cats (257 with ticks) from 332 households (236 with fleas) were included. Ixodes ricinus (78%) and Rhipicephalus sanguineus complex (18%) ticks were the most commonly identified. Tick and flea counts were lower in the fluralaner plus moxidectin group than in the fipronil group throughout the study and the efficacy of fluralaner plus moxidectin exceeded 97 and 98%, respectively. At 12 weeks, 94.1 and 93.3% of cats from the fluralaner plus moxidectin and 92.2 and 60.3% of cats from the fipronil group were free of ticks and fleas, respectively. Fluralaner plus moxidectin was non-inferior to fipronil (P < 0.0001) at all assessments and superior to fipronil at 2 and 8 weeks for the proportion of cats free of ticks (P < 0.0001). Fluralaner plus moxidectin was superior to fipronil for the proportion of both households and cats free of fleas (P < 0.0001). Both products were safe and well tolerated.. A single application of fluralaner plus moxidectin spot-on was well tolerated by cats and highly effective for 12 weeks against ticks and fleas. Fluralaner plus moxidectin was non-inferior to fipronil for the proportion of ectoparasite-free and consistently superior to fipronil in controlling fleas.

Topics: Administration, Topical; Animals; Cat Diseases; Cats; Flea Infestations; Germany; Insecticides; Isoxazoles; Ixodes; Macrolides; Ownership; Pyrazoles; Random Allocation; Rhipicephalus sanguineus; Single-Blind Method; Spain; Tick Infestations; Treatment Outcome

Topics: Administration, Topical; Animals; Antiparasitic Agents; Cat Diseases; Cats; Europe; Female; Flea Infestations; Imidazoles; Isoxazoles; Ivermectin; Macrolides; Male; Neonicotinoids; Nitro Compounds; Pyrazoles; Tick Infestations; Treatment Outcome

Topics: Animals; Antinematodal Agents; Capillaria; Cat Diseases; Cats; Dog Diseases; Dogs; Drug Combinations; Imidazoles; Macrolides; Neonicotinoids; Nitro Compounds; Respiratory System

Notoedric mange (feline scabies) is a rare, but highly contagious disease of cats and kittens caused by Notoedres cati (N. cati), which can infest other animals and also humans. The study objective was to determine the efficacy and safety of 10 % imidacloprid/ 1 % moxidectin (Advocate®/Advantage® Multi spot-on for cats) against natural N. cati infestation in cats. Sixteen cats were randomly assigned to treatment group or negative control using pre-treatment mite counts. The treatment group received a single spot on treatment of the investigational veterinary product (IVP) according to label instructions. The control group stayed untreated. Five cats from the negative control were treated with the IVP at the end of the study and observed for 28 days to increase the treatment group. Skin scrapings and mite counts were performed 28 days post treatment (p.t.). Notoedric skin lesion assessments with clinical scoring were performed regularly. Five animals had to be removed prematurely from the study population due to different reasons. The number of viable N. cati mites in all treated animals 28 days p.t. was zero compared with 2.8 ± 3.0 in the negative control, being significantly lower for treated cats (p = 0.0019, Wilcoxon test). The resulting efficacy was 100 %. Clinical cure based on skin lesion assessment was achieved 28 days p.t. in 100 % of all treated animals completing 28 study days. The IVP was well tolerated and applied at the minimal therapeutic dose (10 mg imidacloprid/1 mg moxidectin/kg body weight) a high therapeutic efficacy in curing N. cati infestations and feline scabies clinical symptoms was recorded.

Topics: Acaricides; Administration, Topical; Animals; Cat Diseases; Cats; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Imidazoles; Macrolides; Mite Infestations; Neonicotinoids; Nitro Compounds; Parasite Load; Sarcoptidae; Skin; Treatment Outcome

Ancylostoma ceylanicum is a common zoonotic hookworm of dogs and cats, especially in the Asia-Pacific region. The objective of this study was to determine the efficacy of a spot on combination product containing imidacloprid 10% and moxidectin 1% (Advocate(®)/Advantage(®) Multi, Bayer Animal Health) against A. ceylanicum in experimentally infected cats. Sixteen kittens were each subcutaneously injected with 100 infective third-stage larvae of A. ceylanicum. Kittens were stratified by egg count and randomly allocated into control and treatment groups. The kittens in the treatment group were each treated with a spot on combination of 10% (w/v) imidacloprid and 1% (w/v) moxidectin, administered topically at recommended label dose rates. The kittens in the control group were not treated. Egg counts were performed daily until the end of the study period and compared for the treated and control groups. No eggs were detected in the treated group of kittens within 4 days of treatment and faecal samples from this group remained negative throughout the rest of the study, resulting in a treatment efficacy (egg reduction) of 100% (P<0.0001). The egg counts remained high (993 ± 666 epg) in the untreated control group for the rest of the study period. This study demonstrated that based on faecal egg count reduction, the spot on combination containing imidacloprid 10% (w/v) and moxidectin 1% (w/v) (Advocate(®)/Advantage(®) Multi, Bayer Animal Health) given at the recommended dose is highly effective against infection with A. ceylanicum in cats.

Topics: Administration, Topical; Ancylostoma; Ancylostomiasis; Animals; Antinematodal Agents; Cat Diseases; Cats; Drug Combinations; Feces; Female; Imidazoles; Larva; Macrolides; Neonicotinoids; Nitro Compounds; Parasite Egg Count; Skin Diseases, Parasitic; Treatment Outcome

The nematode Capillaria aerophila (Trichuroidea, Trichuridae) affects the respiratory system of cats and other animals and occasionally of human beings. Infected cats may show bronchovesicular sounds, inflammation, sneezing, wheezing and, chronic cough and, sometimes, bronchopneumonia and respiratory failure. The present study evaluated the efficacy and safety of the antiparasitic spot-on formulation containing imidacloprid 10%/moxidectin 1 % (Advocate®, Bayer Animal Health) in the treatment of natural feline infection with the lungworm C. aerophila. The efficacy of Advocate® administered once was tested on days 7 ± 1 and 11 ± 1 following treatment at day 0 and compared to faecal egg counts on days -6 ± 1 and -2 ± 1. Overall, 36 cats treated either with Advocate® (treatment group, n = 17 cats) or left untreated (control group, n = 19 cats) were included in the study. Geometric means of faecal egg counts values in eggs per gram of faeces were 124.03 prior to treatment and 0.26 posttreatment in treatment group, while 107.03 and 123.94 pre- and posttreatment in the untreated cats. Post-baseline egg counts showed a 99.79 % reduction in Advocate®-treated animals in comparison with cats which were left untreated. Also, treated cats showed no adverse events. This trial demonstrated that Advocate® spot-on formulation is safe and effective in the treatment of feline lung capillariosis caused by C. aerophila.

Topics: Animals; Anthelmintics; Capillaria; Cat Diseases; Cats; Drug Combinations; Enoplida Infections; Feces; Imidazoles; Macrolides; Neonicotinoids; Nitro Compounds; Parasite Egg Count

To determine whether monthly topical administration of a combination of 10% imidacloprid and 1% moxidectin would lessen flea (Ctenocephalides felis) transmission of Bartonella henselae among cats.. Controlled trial.. 18 specific pathogen-free cats housed in 3 groups of 6.. 3 enclosures were separated by mesh to allow fleas to pass among groups yet prevent cats from contacting one another. One group was inoculated IV with B henselae, and after infection was confirmed, the cats were housed in the middle enclosure. This infected group was flanked by a group that was treated topically with 10% imidacloprid-1% moxidectin monthly for 3 months and by an untreated group. On days 0, 15, 28, and 42, 100 fleas/cat were placed on each of the 6 cats in the B henselae-infected group. Blood samples were collected from all cats weekly for detection of Bartonella spp via PCR assay, bacterial culture, and serologic assay.. B henselae infection was confirmed in the cats infected IV and in all untreated cats after flea exposure; none of the cats treated with the imidacloprid-moxidectin combination became infected.. In this setting, monthly topical administration of 10% imidacloprid-1% moxidectin reduced flea infestation, compared with infestation in untreated cats, and thus prevented flea transmission of B henselae to treated cats. Regular monthly use of this flea control product in cats may lessen the likelihood of humans acquiring B henselae infection.

Topics: Administration, Topical; Angiomatosis, Bacillary; Animals; Bartonella henselae; Cat Diseases; Cats; Female; Imidazoles; Insecticides; Macrolides; Male; Neonicotinoids; Nitro Compounds; Siphonaptera

The objective of the present study was to evaluate the efficacy and safety of the antiparasitic spot-on formulation containing imidacloprid 10%/moxidectin 1% (Advocate, Bayer) in the treatment of natural feline infection with the lungworm Aelurostrongylus abstrusus (Nematoda, Strongylida). The efficacy of Advocate administered once was tested in comparison to a control oral formulation containing fenbendazole 18.75% (Panacur Intervet) administered over three consecutive days based on larvae per gramme of faeces (LPG), measured on days 28 +/- 2 following treatment and compared to counts on days -6 to -2. In total 24 cats treated either with Advocate (n = 12) or with Panacur (n = 12) were included. Mean LPG postbaseline (days 28 +/- 2) were low in both treatment groups, i.e., 0 LPG for Advocate and 1.3 LPG for Panacur. Reduction of post-baseline larval counts showed Advocate (100% reduction) to be superior in efficacy compared to the control product (99.29% reduction). No treated animals showed adverse events. This trial demonstrated that both Advocate spot-on formulation and Panacur oral paste are safe and effective in the treatment of aelurostrongylosis in cats. Future practical perspectives in feline medicine and the major advantages of the spot-on product compared to the oral paste are discussed.

Topics: Animals; Anthelmintics; Cat Diseases; Cats; Double-Blind Method; Drug Therapy, Combination; Feces; Fenbendazole; Imidazoles; Larva; Macrolides; Metastrongyloidea; Neonicotinoids; Nitro Compounds; Strongylida Infections; Treatment Outcome

A topically applied formulation containing 10% imidacloprid+1% moxidectin (Advocate/Advantage multi) has been developed for monthly application to cats for the prevention of feline heartworm (HW) disease caused by Dirofilaria immitis; and for the treatment and control of flea infestations, ear mite infestations, and intestinal nematode infections. A study model was designed to evaluate the safety of this product in cats harboring adult D. immitis infections. Eighty adult cats (40 males/40 females) were each inoculated with 60 third-stage D. immitis larvae on test day (TD) 1. On TD 243-245 echocardiographic imaging was performed on each cat to confirm and estimate the number of adult D. immitis residing in the cardiovascular system. A total of 35 cats were subsequently eligible for safety evaluation based on inclusion criteria. Four treatment groups were established and randomly selected for treatment: imidacloprid+moxidectin solution at the label dose (n=9) (group 1), imidacloprid+moxidectin solution at 5x the Iabel dose (n=9) (group 2), 6% selamectin topical solution (Revolution) at the label dose (positive control, n=8) (group 3), and topical treatment with placebo (negative control, n=9) (group 4). All cats were treated on TD 250. Treatments for groups 1, 3, and 4 were repeated on TDs 278 and 306. Group 2 cats were euthanized and examined for adult D. immitis on TD 288. All other cats were euthanized and examined for adult D. immitis on TD 334. No adverse events attributable to treatment with the test articles were observed during the study. The geometric mean numbers of adult D. immitis recovered at necropsy from treatment groups 1-4 were 2.9, 3.2., 4.0, and 2.7, respectively. There were no statistically significant differences in the comparison of adult D. immitis recovered at necropsy (ANOVA overall group effect P-value of 0.5356). The results of this study demonstrate that imidacloprid+moxidectin topical solution can be used safely in cats heavily infected with adult D. immitis.

Topics: Animals; Anthelmintics; Cat Diseases; Cats; Dirofilaria immitis; Dirofilariasis; Drug Therapy, Combination; Female; Imidazoles; Ivermectin; Macrolides; Male; Neonicotinoids; Nitro Compounds

Topics: Animals; Cat Diseases; Cats; Drug Therapy, Combination; Imidazoles; Insecticides; Macrolides; Mite Infestations; Neonicotinoids; Nitro Compounds; Treatment Outcome

Topics: Administration, Topical; Ancylostoma; Ancylostomatoidea; Animals; Anthelmintics; Cat Diseases; Cats; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Imidazoles; Insecticides; Larva; Macrolides; Nematode Infections; Neonicotinoids; Nitro Compounds; Toxocara; Treatment Outcome

Topics: Administration, Topical; Animals; Cat Diseases; Cats; Dirofilaria immitis; Dirofilariasis; Drug Therapy, Combination; Ectoparasitic Infestations; Imidazoles; Insecticides; Macrolides; Neonicotinoids; Nitro Compounds; Siphonaptera; Treatment Outcome

Topics: Animals; Antinematodal Agents; Cat Diseases; Cats; Drug Therapy, Combination; Imidazoles; Macrolides; Neonicotinoids; Nitro Compounds; Toxocara; Toxocariasis; Treatment Outcome

Topics: Ancylostomatoidea; Animals; Anthelmintics; Cat Diseases; Cats; Dog Diseases; Dogs; Drug Therapy, Combination; Imidazoles; Macrolides; Nematode Infections; Neonicotinoids; Nitro Compounds; Parasite Egg Count; Toxocara; Treatment Outcome

Topics: Ancylostomatoidea; Animals; Anthelmintics; Cat Diseases; Cats; Drug Therapy, Combination; Hookworm Infections; Macrolides; Praziquantel; Pyrantel; Single-Blind Method; Toxocara; Toxocariasis; Treatment Outcome

Topics: Animals; Anorexia; Antidepressive Agents; Cat Diseases; Cats; Dermatitis; Dirofilaria; Dirofilariasis; Doxycycline; Florida; Insecticides; Macrolides; Male; Mirtazapine; Neonicotinoids; Nitro Compounds; Phylogeny; Skin Diseases, Parasitic

The present study evaluated the therapeutic effectiveness of moxidectin 1.0% (w/v) and imidacloprid 10% (w/v) (Advocate® spot-on solution for cats, Bayer Animal Health) against natural infections with the eyeworm Thelazia callipaeda in cats. This study was conducted as a GCP, negative-controlled, blinded and randomised field study in privately owned cats living in an area in southern Italy where T. callipaeda is enzootic.. The study was carried out in 30 cats (19 females and 11 males, aged from 8 months to 5 years, weighing 1.2-5.2 kg) of different breeds, naturally infected by T. callipaeda. At study inclusion (Day 0), animals were physically examined and the infection level was assessed by examination of both eyes for clinical score and live adult T. callipaeda count. Each cat was weighed and randomly assigned to one of the treatment groups (G1: Advocate, G2: untreated control). Clinical assessments and T. callipaeda adult counts were performed on Day 14. At the study completion visit on Day 28, clinical assessments and counts of T. callipaeda adults and larvae were performed. All cats were daily observed by their owners and general health conditions were recorded during the entire period of the study.. The primary effectiveness variable was the percentage of animals in G1 group (Advocate) showing a complete elimination (parasitological cure) of adult eye worms at Day 14 and Day 28 . The effectiveness of the treatment in the G1 group was 93.3 and 100% at Day 14 and Day 28 , respectively, when compared to group G2. Total worm count reduction from both eyes for Advocate was 96.3% on Day 14 and 100% on Day 28. Clinical data were confirmed by the examination of conjunctival pouch flushing. An overall reduction in the number of cats with lacrimation and conjunctivitis was observed following treatment despite the fact that in a few cats treated with Advocate clinical signs persisted due to the chronic nature of the disease.. Based on the results of the present trial, a single dose of Advocate was found to be safe and highly effective in the treatment of natural T. callipaeda infection in cats.

Topics: Administration, Topical; Animals; Cat Diseases; Cats; Drug Combinations; Eye Diseases; Macrolides; Neonicotinoids; Nitro Compounds; Spirurida Infections; Thelazioidea

Dirofilaria immitis and D. repens are vector-borne parasites of dogs and cats, with zoonotic potential, endemic in many parts of Europe, including Italy. Control and prevention of dirofilariosis are essential points to reduce their diffusion in animals and humans and veterinarians are the main subjects involved in this "battle". With the aim to better understand current practice by veterinarians, an online questionnaire on different aspects of D. immitis and D. repens was sent to companion animal veterinary facilities registered with the Italian Veterinary chamber. The overall response rate was 25%. Approximately 47% had diagnosed at least one case of Dirofilaria spp. in dogs in the last year and approximately 6% had diagnosed at least one case of Dirofilaria spp. in cats. Of the 662 facilities surveyed, 83.8% used serology to diagnose heartworm infection. For the diagnosis of D. repens infection in dogs and cats, a high percentage of facilities relied on an external laboratory. Most recommended beginning prevention of canine heartworm disease in April-May. Topical and injectable moxidectin and oral ivermectin were the two most commonly used preventives for D. immitis in dogs. The drug most commonly used for heartworm adulticide treatment in dogs was melarsomine. This study show that veterinary facilities ians working in an endemic area for D. immitis and D. repens are aware of recent developments in adulticide therapy. Results would suggest however that diagnosis is not always carried out according to what is currently recommended by international guidelines and that the timing for starting prevention may not be optimal.

Topics: Animals; Antinematodal Agents; Cat Diseases; Cats; Dirofilaria immitis; Dirofilaria repens; Dirofilariasis; Dog Diseases; Dogs; Hospitals, Animal; Italy; Ivermectin; Macrolides; Mosquito Vectors; Surveys and Questionnaires; Veterinarians

The efficacy of the fixed combination of fluralaner plus moxidectin for the treatment of Otodectes cynotis infestations was evaluated in cats after topical application.. Sixteen cats experimentally infested with O. cynotis were allocated randomly to two groups of 8 cats each. One group was treated topically with the fixed combination of fluralaner plus moxidectin at the minimum dose rate of 40 mg fluralaner and 2 mg moxidectin/kg body weight. The other group was treated with physiological saline solution. Before and 14 and 28 days after treatment the ears of all cats were examined otoscopically for live mites and for the amount of debris and cerumen. Twenty-eight days after treatment, the cats were sedated and had both ears flushed to obtain the total number of live mites per animal. Efficacy was calculated, based on the results of the ear flushing, by comparing mean live mite counts in the fluralaner plus moxidectin treated group versus the saline group.. A single topical application of the fixed combination of fluralaner plus moxidectin to cats reduced the mean mite counts by 100% (P < 0.001) by 28 days after treatment. No mites were visible during otoscopic examination at either 14 or 28 days after treatment. All fluralaner plus moxidectin treated cats had less ceruminous exudate 28 days after treatment compared to pre-treatment and 14 days after treatment. No treatment related adverse events were observed in any cats enrolled in the study.. Single topical application of the fixed combination of fluralaner plus moxidectin was highly effective against O. cynotis infestations in cats.

Topics: Administration, Topical; Animals; Cat Diseases; Cats; Drug Therapy, Combination; Female; Insecticides; Isoxazoles; Macrolides; Male; Mite Infestations; Otitis Externa; Otoscopy; Pharmaceutical Solutions; Psoroptidae; Random Allocation; Treatment Outcome

Fluralaner provides efficacy against feline ectoparasites following topical administration. Moxidectin is routinely used to treat gastrointestinal nematode infections and prevent heartworm disease caused by Dirofilaria immitis. Praziquantel is routinely used to treat feline tapeworm infections. The safety of a fluralaner plus moxidectin combination topical solution (Bravecto™ Plus, MSD Animal Health) was assessed when administered concurrently with a commercially available praziquantel topical solution (Droncit™ Spot-on, Bayer Animal Health GmbH). The highest dose rates in clinical use were tested.. Concurrent topical administration of a fluralaner plus moxidectin and a praziquantel product did not result in adverse findings. One out of ten cats receiving praziquantel only (control group), and two out of ten cats receiving fluralaner plus moxidectin and praziquantel (treatment group) had dandruff-like flakes in their coat at the application site. Two out of the ten control cats and three cats out of the ten treatment group cats had very small amounts of unidentified material (minute crusts or crumbs) at the application site which was only visible during close inspection.. The concurrent treatment of cats with fluralaner plus moxidectin and praziquantel at the maximum dose in clinical use was well tolerated.

Topics: Acaricides; Administration, Topical; Animals; Anthelmintics; Cat Diseases; Cats; Dirofilariasis; Drug Therapy, Combination; Ectoparasitic Infestations; Female; Insecticides; Isoxazoles; Macrolides; Male; Nematode Infections; Praziquantel; Random Allocation; Treatment Outcome

Lynxacarus radovskyi has been observed in cats in Malaysia; previously treatment with fipronil and moxidectin/imidacloprid spot-on has been described.. To compare the efficacy of two spot-on treatments of moxidectin/imidacloprid, two weeks apart to a single oral dose of fluralaner against Lynxacarus radovskyi and evaluate time to re-infestation.. Thirty cats were assigned to three groups of ten cats each. Group 1 received one 250 mg fluralaner tablet. Group 2 received two doses of moxidectin/imidacloprid spot-on two weeks apart. Group 3 consisted of untreated controls. For each cat, three plucks of about 50 hairs each were collected from three sites (dorsal neck, lateral thigh and perineal/tail region) for a total of nine pluckings every two weeks. Severity of infestation was scored from 0 (no parasite), to 1 (only nonhatched eggs), 2 (both hatched and nonhatched eggs), 3 (<50 mites) and 4 (>50 mites). Efficacy was compared between treatment groups and over time in the same group, and results analysed statistically. Re-infestation was defined as the identification of new eggs or mites on hair pluckings.. Moxidectin/imidacloprid spot-on and oral fluralaner achieved 100% eradication within 28 days. No significant difference was observed between groups 1 and 2; re-infestation occurred by Day 56 in both treatment groups.. A single dose of oral fluralaner or two moxidectin/imidacloprid spot-on treatments two weeks apart are efficacious in the eradication of L. radovskyi in cats and able to prevent re-infestation for at least 42 days post-treatment.

Topics: Acaricides; Administration, Oral; Administration, Topical; Animals; Cat Diseases; Cats; Drug Combinations; Female; Hair; Imidazoles; Isoxazoles; Macrolides; Male; Mite Infestations; Neonicotinoids; Nitro Compounds

Rapidly growing mycobacteria (RGM) infections in cats typically manifest as a panniculitis, requiring long-term antimicrobial therapy for resolution. The search for novel antimicrobial therapies to reduce treatment duration and improve the rate of clinical resolution is imperative. Accordingly, RGM isolates underwent susceptibility testing to some avermectins and other antibacterial drugs currently available.. Five Mycobacterium fortuitum and six Mycobacterium smegmatis isolates obtained from Australian cats underwent susceptibility testing by microbroth dilution to ivermectin, moxidectin, ceftiofur and florfenicol.. All isolates were resistant to the highest concentrations of ivermectin, moxidectin and ceftiofur tested (1024 µg/ml, 256 μg/ml and 32 μg/ml, respectively). All isolates of M fortuitum were resistant to the highest concentration of florfenicol tested (128 µg/ml). The minimum inhibitory concentration range of florfenicol that inhibited growth of M smegmatis isolates was 32-64 µg/ml.. All drugs appear to have no efficacy in vitro for the treatment of RGM infections.

Topics: Animals; Anti-Bacterial Agents; Australia; Cat Diseases; Cats; Cephalosporins; Drug Combinations; Drug Resistance, Bacterial; Ivermectin; Macrolides; Microbial Sensitivity Tests; Mycobacterium; Mycobacterium fortuitum; Mycobacterium Infections; Thiamphenicol

The aim of this study was to sequence all exons of the ABCB1 (MDR1) gene in cats that had experienced adverse reactions to P-glycoprotein substrate drugs (phenotyped cats). Eight phenotyped cats were included in the study consisting of eight cats that experienced central nervous system toxicosis after receiving ivermectin (n = 2), a combination product containing moxidectin and imidacloprid (n = 3), a combination product containing praziquantel and emodepside (n = 1) or selamectin (n = 2), and 1 cat that received the product containing praziquantel and emodepside but did not experience toxicity (n = 1). Fifteen exons contained polymorphisms and twelve exons showed no variation from the reference sequence. The most significant finding was a nonsense mutation (ABCB11930_1931del TC) in one of the ivermectin-treated cats. This cat was homozygous for the deletion mutation. All of the other phenotyped cats were homozygous for the wild-type allele. However, 14 missense mutations were identified in one or more phenotyped cats. ABCB11930_1931del TC was also identified in four nonphenotyped cats (one homozygous and three heterozygous for the mutant allele). Cats affected by ABCB11930_1931del TC would be expected to have a similar phenotype as dogs with the previously characterized ABCB1-1Δ mutation.

Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Cat Diseases; Cats; Central Nervous System Diseases; Cloning, Molecular; Codon, Nonsense; Depsipeptides; Exons; Homozygote; Imidazoles; Ivermectin; Macrolides; Neonicotinoids; Nitro Compounds; Polymorphism, Single Nucleotide; Praziquantel; Sequence Analysis, DNA

Infection of cats with Dirofilaria immitis causes seroconversion on antibody tests and pulmonary pathology, often without subsequent development of adult heartworms. Consistent administration of topical 10% imidacloprid-1% moxidectin has been shown to result in sustained plasma levels of moxidectin in cats after three to five treatments, a pharmacokinetic behavior known as "steady state".. To evaluate the ability of moxidectin at "steady state" to protect cats from subsequent infection with D. immitis, cats (n = 10) were treated with the labeled dose of topical 10% imidacloprid-1% moxidectin for four monthly treatments. Each cat was inoculated with 25 third-stage larvae of D. immitis 7, 14, 21, and 28 days after the last treatment; non-treated cats (n = 9) were inoculated on the same days, serving as infection controls. Blood samples were collected from each cat from 1 month prior to treatment until 7 months after the final inoculation and tested for antibody to, and antigen and microfilaria of, D. immitis.. Measurement of serum levels of moxidectin confirmed steady state in treated cats. Cats treated with topical 10% imidacloprid-1% moxidectin prior to trickle inoculation of D. immitis L3 larvae throughout the 28 day post-treatment period remained negative on antibody and antigen tests throughout the study and did not develop gross or histologic lesions characteristic of heartworm infection. A majority of non-treated cats tested antibody positive by 3-4 months post infection (6/9) and, after heat treatment, tested antigen positive by 6-7 months post-infection (5/9). Histologic lesions characteristic of D. immitis infection, including intimal and medial thickening of the pulmonary artery, were present in every cat with D. immitis antibodies (6/6), although adult D. immitis were confirmed in only 5/6 antibody-positive cats at necropsy. Microfilariae were not detected at any time.. Taken together, these data indicate that prior treatment with 10% imidacloprid-1% moxidectin protected cats from subsequent infection with D. immitis for 28 days, preventing both formation of a detectable antibody response and development of pulmonary lesions by either immature stages of D. immitis or young adult heartworms.

Topics: Administration, Topical; Animals; Anthelmintics; Antibodies, Helminth; Antigens, Helminth; Cat Diseases; Cats; Chemoprevention; Dirofilaria immitis; Dirofilariasis; Macrolides; Plasma; Treatment Outcome

Safety of concomitant use of veterinary products is of clinical interest. A series of studies was performed to evaluate the chemical compatibility and short term dermal and systemic safety of an imidacloprid/flumethrin collar (Seresto(®)/ Foresto(®), Bayer) used concomitantly with spot-on or tablet formulations.Chemical compatibility was evaluated in-vitro (study reference A) on collar pieces, followed by two small, non-controlled clinical studies (study reference B) in both, cats and dogs. The studies showed, that certain solvents affected the collar in-vitro, but not in their marketed formulations.Dermal and systemic safety of different spot-on or tablet formulations was first evaluated in a small, non-controlled clinical study (study reference C) in cats and dogs, via clinical observations only, followed by controlled clinical safety studies of concomitant use with imidacloprid/ moxidectin (Advocate(®)/ Advantage(®) Multi, Bayer) in dogs and cats (study reference D) and emodepside/ praziquantel (Profender(®), Bayer) in cats (study reference E), assessing safety aspects by clinical observations and statistical analyses of hematology and clinical chemistry parameters compared to baseline values and between treated and control groups.Dermal safety findings over all clinical studies (study references B to E) matched those already described for the respective products and included transient cosmetic changes (oily hair and crystal formation) at the site of spot-on application and broken hair, transient alopecia and skin alterations at the site of collar application. There were no indications of these findings aggravating under the conditions of concurrent use. There were no systemic safety findings of clinical significance in any of the clinical safety studies (study reference C to E). Assessment of blood parameters revealed some deviations from baseline levels and from the reference range in dogs as well as in cats, but no clinical relevance could be deduced. Hematology and clinical chemistry results confirmed the safety of the concomitant treatment. It is concluded that Seresto(®) is chemically compatible with solvents used in major spot-on formulations on the market and is dermally and systemically safe for adult dogs and cats when used concomitantly with Advocate(®) and Profender(®) spot-on formulations.

Topics: Administration, Topical; Animals; Cat Diseases; Cats; Depsipeptides; Dog Diseases; Dogs; Imidazoles; Insecticides; Macrolides; Neonicotinoids; Nitro Compounds; Praziquantel; Pyrethrins; Solvents

This study presents clinical findings after oral ingestion of Toxocara cati eggs which resulted in rapid pulmonary lung migration and parenchymal disease, noted on clinically relevant diagnostic methods. Further, the study investigated the efficacy of pre-infection applications of preventative medication on larval migration through the lungs. A third aim of the study was to determine if adult cats infected with T. cati developed lung disease. Cats in infected groups were administered five oral doses of L3 T. cati larvae. Four-month-old specific pathogen free (SPF) kittens were divided into three groups (six per group): an infected untreated group, an uninfected untreated control group, and an infected treated group (topical moxidectin and imidacloprid, Advantage Multi for Cats, Bayer Healthcare LLC). Six 2- to 3-year-old adult multiparous female SPF cats were an infected untreated adult group. The cats were evaluated by serial CBCs, bronchial-alveolar lavage (BAL), fecal examinations, thoracic radiographs, and thoracic computed tomography (CT) scans and were euthanized 65 days after the initial infection. Adult T. cati were recovered in infected untreated kittens (5/6) and infected untreated adults (5/6) in numbers consistent with natural infections. Eggs were identified in the feces of most but not all cats with adult worm infections. No adult worms were identified in the uninfected controls or the infected treated group. All cats in the infected groups, including treated cats and untreated cats without adult worms, had lung pathology based on evaluation of radiography, CT scans, and histopathology. The infected cats demonstrated a transient peripheral eosinophilia and marked eosinophilic BAL cytology, but normal bronchial reactivity based on in vivo CT and in vitro ring studies. Lung lesions initially identified by CT on day 11 were progressive. Thoracic radiographs in infected cats had a diffuse bronchial-interstitial pattern and enlarged pulmonary arteries. Pulmonary arterial, bronchial, and interstitial disease were prominent histological findings. Infected treated cats had a subtle attenuation but not prevention of lung disease compared to infected cats. Significant lung disease in kittens and adult cats is associated with the early arrival of T. cati larvae in the lungs and is independent of the development of adult worms in the intestine. These data suggest that while the medical prevention of the development of adult parasites after oral exposure

Topics: Animals; Bronchoalveolar Lavage; Cat Diseases; Cats; Feces; Female; Imidazoles; Insecticides; Larva; Lung; Macrolides; Male; Neonicotinoids; Nitro Compounds; Ovum; Pulmonary Fibrosis; Radiography, Thoracic; Specific Pathogen-Free Organisms; Tomography, X-Ray Computed; Toxocara; Toxocariasis

In April 2010, pruritic symptoms were recognized in 3 privately-owned Siamese cats raised in Gwangju, Korea. Examination of ear canals revealed dark brown, ceruminous otic exudates that contain numerous live mites at various developmental stages. Based on morphological characteristics of adult mites in which caruncles were present on legs 1 and 2 in adult females and on legs 1, 2, 3, and 4 in adult males while the tarsus of leg 3 in both sexes was equipped with 2 long setae, the mite was identified as Otodectes cynotis. Ten ear mite-free domestic shorthaired cats were experimentally infected with O. cynotis to evaluate the efficacy of 10% imidacloprid/1% moxidectin spot-on. Live mites were recovered from 1 of 10 treated cats on day 9 post-treatment (PT) while no live mites were observed from the ear canals of treated cats on days 16 and 30 PT. The efficacy of 10% imidacloprid/1% moxidectin spot-on on O. cynotis in cats was, therefore, 90% on day 9 and 100% on days 16 and 30 PT. This is the first report of otodectosis in 3 cats naturally infested with O. cynotis in Gwang-ju, Korea. Both natural and experimental infestations were successfully treated with 10% imidacloprid/1% moxidectin spot-on.

Topics: Acaricides; Administration, Topical; Animals; Cat Diseases; Cats; Ear Diseases; Female; Imidazoles; Macrolides; Male; Mite Infestations; Neonicotinoids; Nitro Compounds; Psoroptidae; Republic of Korea; Solutions; Treatment Outcome

Sarcoptes scabiei infestation is rare in cats.. To report the clinical presentations and treatments of cats infested with S. scabiei.. Five cats that presented with progressive and nonresponsive crusting lesions on the concave and convex aspects of the pinnae are included in this series. Other dermatological manifestations recorded were crusts on the bridge of the nose (five of five), crusty pododermatitis (three of five), crusty lesions on the tail (one of five) and pruritic erythematous papules on the arms and/or thighs of the owners (five of five). None of the cats was living in a household with a dog.. Sarcoptic (S. scabiei) mange was diagnosed based on the identification of S. scabiei in deep skin scrapings. A spot-on application of 1.0% moxidectin and 10% imidacloprid (0.1 mL/kg) was administered every 2 weeks for three applications. All cats were re-evaluated at the time of treatment.. All five cats and their owners improved after the first application and reached clinical remission after the third application. Deep skin scrapings from all cats were negative for S. scabiei after the first application. No clinical adverse effects or abnormalities on routine blood tests were noted during the study period. No reinfestation was reported during the follow-up period of 6 months after treatment.. Although sarcoptic mange is rare in cats, it should be considered as a differential diagnosis for cats presenting with crusting lesions on the pinnae and nose and crusty pododermatitis. A spot-on preparation of moxidectin and imidacloprid was used successfully to treat cats with S. scabiei infestation.

Topics: Administration, Topical; Animals; Cat Diseases; Cats; Drug Combinations; Female; Imidazoles; Insecticides; Macrolides; Male; Neonicotinoids; Nitro Compounds; Scabies; Taiwan

Two studies were conducted to evaluate and compare the efficacy of imidacloprid + moxidectin and selamectin topical solutions against the KS1 flea strain infesting cats. In both studies the treatment groups were comprised of non-treated controls, 6% w/v selamectin (Revolution®; Pfizer Animal Health) topical solution and 10% w/v imidacloprid + 1% w/v moxidectin (Advantage Multi® for Cats, Bayer Animal Health) topical solution. All cats were infested with 100 fleas on Days -2, 7, 14, 21, and 28. The difference in the studies was that in study #1 efficacy evaluations were conducted at 24 and 48 hours post-treatment or post-infestation, and in study #2 evaluations were conducted at 12 and 24 hours.. In study #1 imidacloprid + moxidectin and the selamectin formulation provided 99.8% and 99.0% efficacy at 24 hours post-treatment. On day 28, the 24 hour efficacy of the selamectin formulation dropped to 87.1%, whereas the imidacloprid + moxidectin formulation provided 98.9% efficacy. At the 48 hour assessments following the 28 day infestations, efficacy of the imidacloprid + moxidectin and selamectin formulations was 96.8% and 98.3% respectively. In study # 2 the efficacy of the imidacloprid + moxidectin and selamectin formulations 12 hours after treatment was 100% and 69.4%, respectively. On day 28, efficacy of the imidacloprid + moxidectin and selamectin formulations 12 hours after infestation was 90.2% and 57.3%, respectively. In study #2 both formulations provided high levels of efficacy at the 24 hour post-infestation assessments, with selamectin and imidacloprid + moxidectin providing 95.3% and 97.5% efficacy, following infestations on day 28.. At the 24 and 48 hour residual efficacy assessments, the imidacloprid + moxidectin and selamectin formulations were similarly highly efficacious. However, the imidacloprid + moxidectin formulation provided a significantly higher rate of flea kill against the KS1 flea strain infesting cats at every 12 hour post-infestation residual efficacy assessment. Both formulations should provide excellent flea control for an entire month on cats.

Topics: Animals; Antiparasitic Agents; Cat Diseases; Cats; Ctenocephalides; Drug Evaluation; Drug Therapy, Combination; Female; Flea Infestations; Imidazoles; Insecticides; Ivermectin; Macrolides; Male; Neonicotinoids; Nitro Compounds; Random Allocation; Treatment Outcome

Throughout the end of March to beginning of May 2006, 212 owned cats and 608 owned dogs from a heavy endemic area for canine heartworm (HW) disease in northern Italy have been examined to assess HW infection prevalence. Both cats and dogs were clinically examined and blood samples were taken from each animal to be examined for HW antibody (Ab). Ab-positive cats were further examined for circulating microfilariae, HW antigens (Ag) and by echocardiography (ECHO) to assess the presence of adult worms. Dogs were clinically examined and blood samples taken from each animal were examined for circulating microfilariae and for HW Ag. Ten cats (4.7%) were found Ab positive. Of these, 6 cats were Ag positive (2.6%) and in 4 (1.8%) the worms were visualized by ECHO. HW prevalence in dogs was 36% (221/608). One hundred and seventy-six (29%) were both microfilaraemic and Ag positive, 40 (7%) had occult infections (no circulating microfilariae) and 7 (1%) were microfilaraemic but Ag negative. Upon owners' consent, 132 cats (including cats Ab and/or Ag and ECHO positive) were prophylactically treated against HW disease with an imidacloprid/moxidectin spot-on combination (10% imidacloprid/1% moxidectin) monthly administered for 6 months. Cats were re-examined for HW infection in November, 1 month after the last drug administration, and in May-June 2007, 7-8 months after the last treatment. All 122 cats found HW negative before treatment, were found negative at the two examinations at the end of study. The 4 cats Ab positive, 2 cats Ab and Ag positive and 1 Ab, Ag and ECHO positive at the beginning of treatment were found negative. Throughout the treatment, transitory hypersalivation and generic signs of annoyance were reported by owners in 6 cats (4.5%). All signs regressed spontaneously.

Topics: Animals; Cat Diseases; Cats; Dirofilaria immitis; Dirofilariasis; Drug Therapy, Combination; Female; Filaricides; Imidazoles; Macrolides; Male; Neonicotinoids; Nitro Compounds

Sixteen controlled laboratory studies, involving 420 kittens and cats, were conducted to evaluate the efficacy and safety of topically applied formulations of imidacloprid and moxidectin for the prevention of feline heartworm disease, treatment of flea infestations and treatment and control of intestinal nematodes. Unit-dose applicators and the dosing schedule used in these studies were designed to provide a minimum of 10mg imidacloprid and 1mg moxidectin/kg. Treatments were applied topically by parting the hair at the base of the skull and applying the solution on the skin. Imidacloprid treatment alone did not display activity against Dirofilaria immitis or intestinal nematodes and moxidectin treatment alone provided little or no activity against adult Ctenocephalides felis infestations. The formulation containing 10% imidacloprid and 1% moxidectin was 100% efficacious against the development of adult D. immitis infections when cats were treated 30 days after inoculation with third-stage larvae. A single treatment with this formulation also provided 88.4-100% control of adult C. felis for 35 days. Imidacloprid/moxidectin was 100% efficacious against adult Toxocara cati and 91.0-98.3% efficacious against immature adults and fourth-stage T. cati larvae. The formulation provided 98.8-100% efficacy against adult Ancylostoma and immature adults and third-stage A. tubaeforme larvae. Monthly topical application with 10% imidacloprid/1% moxidectin is convenient, efficacious and safe for the prevention of feline heartworm disease, treatment of flea infestation and for the treatment and control of intestinal nematode infections of cats.

Topics: Administration, Topical; Animals; Antinematodal Agents; Cat Diseases; Cats; Dirofilariasis; Dose-Response Relationship, Drug; Drug Administration Schedule; Ectoparasitic Infestations; Female; Filaricides; Imidazoles; Insecticides; Intestinal Diseases, Parasitic; Life Cycle Stages; Macrolides; Male; Nematode Infections; Neonicotinoids; Nitro Compounds; Treatment Outcome

Topics: Adverse Drug Reaction Reporting Systems; Animals; Anthelmintics; Anti-Inflammatory Agents, Non-Steroidal; Blindness; Cat Diseases; Cats; Databases, Factual; Dog Diseases; Dogs; Drug Overdose; Enrofloxacin; Equipment Failure; Etodolac; Fluoroquinolones; Horse Diseases; Horses; Keratoconjunctivitis Sicca; Legislation, Drug; Macrolides; Quinolones; Syringes; United States; United States Food and Drug Administration; Veterinary Drugs

Multiple cutaneous xanthomas, associated with fasting hyperlipidaemia, are described in a 9-month-old domestic long-haired cat. A severely pruritic, papular, and crusting dermatitis affecting the head and neck, initially diagnosed as lesions of the eosinophilic granuloma complex, progressively developed on the head and pinnae. Pruritus was controlled with administration of prednisolone and chlorambucil. Repeat histological examination confirmed the diagnosis of cutaneous xanthoma and concurrent mild demodicosis. Marked fasting hypercholesterolaemia, hypertriglyceridaemia and transient hyperglycaemia were subsequently confirmed. Treatment for hyperlipidaemia and xanthomas with a low-fat diet (Hill's Feline r/d) and the previously unreported treatment for feline demodicosis of daily oral milbemycin were commenced. Multiple pink, alopecic plaques and papules gradually regressed, however pruritus recurred if immunosuppressive treatment was reduced, and well-demarcated areas of alopecia developed on the head, limbs and trunk, despite negative skin scrapings for demodex mites. Fungal culture of hair samples yielded Microsporum canis. All cutaneous lesions resolved with the addition of griseofulvin to the treatment regimen. Concurrent corneal ulceration and keratoconjunctivitis sicca ultimately resolved with treatment, including topical cyclosporin. Diabetes mellitus developed 6 months after resolution of skin lesions. No cutaneous or ocular abnormalities were present 6 months later with continued low-fat diet and insulin administration, although transient recurrence of papules and pruritus occurred after inadvertent access to a fatty meal. An underlying primary hyperlipidaemia was suspected, causing pruritic xanthomas. This may represent the first report of concurrent cutaneous xanthomas, demodicosis and dermatophytosis in a cat.

Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Cat Diseases; Cats; Dermatomycoses; Diagnosis, Differential; Griseofulvin; Hyperlipidemias; Insecticides; Macrolides; Male; Microsporum; Mite Infestations; Xanthomatosis

Anthelmintic efficacy of milbemycin D was evaluated against Toxocara cati and Ancylostoma tubaeforme in domestic cats. Twelve cats naturally infected with each nematode species were allocated among 2 groups of 6 animals each, and milbemycin D was orally administered to the 2 groups of cats in doses of 0.05 mg/kg and 0.1 mg/kg body weight, respectively. In all the cats infected with T. cati, fecal egg counts decreased followed by their disappearance from the feces and 2-35 worms were excreted into the feces after the medication in both doses of 0.05 mg/kg and 0.1 mg/kg. At postmortem of these medicated groups, no worms were detected from 4 cats of each group, but 1 and 2 immature worms were recovered from the other 2 cats respectively. In the cats infected with A. tubaeforme, fecal egg counts decreased followed by the disappearance from the feces and 2-62 worms were excreted into the feces in all the cats of the 2 groups, no nematodes remaining at postmortem. These results indicate that milbemycin D is fully effective against T. cati and A. tubaeforme in cats in a dose of 0.05-0.1 mg/kg.

Topics: Ancylostomiasis; Animals; Anthelmintics; Anti-Bacterial Agents; Cat Diseases; Cats; Feces; Female; Macrolides; Male; Parasite Egg Count; Toxocariasis